
    
      To determine the antitumor activity, based on the confirmed objective response rate, of
      KOS-862, administered intravenously weekly for 3 weeks every 4 weeks, in patients with
      non-small cell lung cancer (NSCLC) whose disease has progressed following initial
      chemotherapy for advanced or metastatic disease.
    
  